• metastatic/advanced - esophageal cancer (mEC)
• mEC - (neo)adjuvant (NA) 1
• mEC - 1st line (L1) 1
• mEC - 2nd line (L2) 3
• gastric or gastroesophageal junction cancer (GC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab plus SoC

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs placebo plus SoC

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;